Defence Therapeutics Inc. has announced that it has achieved the first milestone in its collaboration agreement with Orano Support SAS to develop radio-immunoconjugates using Defence's intracellular targeting technology. The first milestone involved synthesizing the AccuTOX peptide containing the DOTA chelator and the Azide moiety. The collaboration aims to develop novel radio-based therapies that combine Defence's targeting technology with cancer-targeting antibodies to improve specificity, selectivity, and therapeutic efficacy. The global radiopharmaceuticals market is projected to reach US$ 13.818 billion by 2028, and the global cancer immunotherapy market is expected to reach USD 196.45 billion by 2030. Orano is a multinational company focused on nuclear materials and energy solutions. Defence Therapeutics is a biotechnology company working on next-generation vaccines and ADC products.
Mon, 17 Jul 2023 16:40:04 GMT | Marketscreener.com